Polycomb target genes are silenced in multiple myeloma.

PloS One
Antonia KalushkovaHelena Jernberg-Wiklund

Abstract

Multiple myeloma (MM) is a genetically heterogeneous disease, which to date remains fatal. Finding a common mechanism for initiation and progression of MM continues to be challenging. By means of integrative genomics, we identified an underexpressed gene signature in MM patient cells compared to normal counterpart plasma cells. This profile was enriched for previously defined H3K27-tri-methylated genes, targets of the Polycomb group (PcG) proteins in human embryonic fibroblasts. Additionally, the silenced gene signature was more pronounced in ISS stage III MM compared to stage I and II. Using chromatin immunoprecipitation (ChIP) assay on purified CD138+ cells from four MM patients and on two MM cell lines, we found enrichment of H3K27me3 at genes selected from the profile. As the data implied that the Polycomb-targeted gene profile would be highly relevant for pharmacological treatment of MM, we used two compounds to chemically revert the H3K27-tri-methylation mediated gene silencing. The S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin (DZNep) and the histone deacetylase inhibitor LBH589 (Panobinostat), reactivated the expression of genes repressed by H3K27me3, depleted cells from the PRC2 component EZH2 and induce...Continue Reading

References

Aug 1, 1967·Proceedings of the Society for Experimental Biology and Medicine·Y MatsuokaD Pressman
Feb 22, 2002·The New England Journal of Medicine·Robert A KyleL Joseph Melton
Jul 9, 2003·Immunological Reviews·Karin VanderkerkenBen Van Camp
Nov 25, 2003·Blood·William MatsuiRichard J Jones
Apr 8, 2004·Neoplasia : an International Journal for Oncology Research·Daniel R RhodesArul M Chinnaiyan
Jul 3, 2004·Genes & Development·Antonis KirmizisPeggy J Farnham
Aug 19, 2004·Cell·Merel E Valk-LingbeekMaarten van Lohuizen
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Dec 17, 2005·Nature·Emmanuelle ViréFrançois Fuks
Apr 19, 2006·Genes & Development·Adrian P BrackenKristian Helin
Aug 2, 2006·Biochemical Pharmacology·Tjadine M HollingPeter J van den Elsen
Dec 19, 2006·Nature Reviews. Genetics·Yuri B Schwartz, Vincenzo Pirrotta
Jan 4, 2007·Nature Genetics·Martin WidschwendterPeter W Laird
Aug 19, 2007·Cancer Cell·Jonathan J KeatsP Leif Bergsagel
Oct 4, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tjadine M HollingPeter J Van den Elsen
Nov 17, 2007·Cancer Research·Jindan YuArul M Chinnaiyan
Nov 24, 2007·Current Opinion in Cell Biology·Laura A Buttitta, Bruce A Edgar
Oct 17, 2008·Experimental Hematology·Marina TshuikinaFredrik Oberg
Oct 22, 2008·Nature Cell Biology·Klaus H HansenKristian Helin
Feb 24, 2009·Blood·Brendan M WeissW Michael Kuehl
Mar 31, 2009·Nature Genetics·Gijs van HaaftenP Andrew Futreal
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·H Miles PrinceSimon J Harrison
Jun 11, 2009·Molecular Cancer Therapeutics·Tina Branscombe MirandaPeter A Jones

❮ Previous
Next ❯

Citations

May 9, 2014·Epigenomics·Charlotte PawlynGareth J Morgan
Jul 21, 2014·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hirohito Yamaguchi, Mien-Chie Hung
Aug 22, 2013·Metallomics : Integrated Biometal Science·Lisa PassantinoMax Costa
Nov 27, 2014·Expert Opinion on Therapeutic Targets·Christian MayrTobias Kiesslich
Jun 9, 2015·Expert Review of Anticancer Therapy·Paul G RichardsonJesús F San-Miguel
Oct 28, 2015·Expert Review of Clinical Pharmacology·Paul G RichardsonJesús F San-Miguel
May 26, 2015·Expert Opinion on Investigational Drugs·Richard L Momparler, Sylvie Côté
Sep 10, 2014·Journal of Hematology & Oncology·Shanique EdwardsPing Xie
Mar 27, 2012·The Journal of Nutritional Biochemistry·Rihua CongRuqian Zhao
Sep 29, 2011·Molecular Cancer·Rossella RotaFranco Locatelli
Jun 28, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Liang ShenPei-Shu Liu
Jun 30, 2015·Experimental Hematology·Naoya MimuraKenneth C Anderson
Feb 22, 2012·Upsala Journal of Medical Sciences·Helena Jernberg-Wiklund, Kenneth Nilsson
Dec 24, 2011·BMC Genomics·Michael A J ZiegerMu Wang
Mar 16, 2012·Epigenetics : Official Journal of the DNA Methylation Society·Sarah E MahoneyScott J Diede
Oct 11, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Meena KanduriRichard Rosenquist
Sep 26, 2014·PloS One·Jérémie GaudichonBrigitte Sola
Dec 25, 2015·Journal of the American Society of Nephrology : JASN·Xiaoxu ZhouShougang Zhuang
Jan 12, 2017·Expert Review of Hematology·Jacob P LaubachPaul G Richardson
Mar 23, 2017·Cancer Letters·Fahimeh ShahabipourAmirhossein Sahebkar
Dec 4, 2014·Therapeutic Advances in Hematology·Claudia V Andreu-Vieyra, James R Berenson
Sep 2, 2019·Journal of Biomedical Science·Dong-Yan TsaiKuo-I Lin
Oct 5, 2019·Blood·Lawrence H Boise
Oct 27, 2015·Oncotarget·Laurie HerviouJérôme Moreaux
Jun 19, 2017·Journal of Hematology & Oncology·Nasrin RastgooHong Chang
Dec 18, 2018·Biomarker Research·Rosemarie Tremblay-LeMayHong Chang
Feb 15, 2019·Epigenomes·Mohammad AlzrigatJonathan D Licht
Sep 8, 2018·Blood Cancer Journal·Hiroto OhguchiKenneth C Anderson
Nov 23, 2019·Journal of Hematology & Oncology·Boheng Li, Wee-Joo Chng

❮ Previous
Next ❯

Methods Mentioned

BETA
immunoprecipitation
ISS
acetylation
flow cytometry
FACS
electrophoresis
biopsy
ChIP
PCR

Software Mentioned

Oncomine
Mx3005P
GSEA

Related Concepts

Related Feeds

B cells: Gene Expression

B lymphocytes are white blood cells that play a role in the adaptive immune system by secreting antibodies. Here is the latest research on gene expression in B cells.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

B cell Differentiation

Depending on the signal received through the B cell receptor and other receptors, B cells differentiate into follicular or marginal zone B cells. Here is the latest research pertaining to this differentiation process.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.